SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (569)11/3/2003 6:14:46 PM
From: dalroi  Read Replies (2) of 3661
 
ESPR


Bad Esperion data confirmed
11/03/03 04:07 PM ET
(By Adam Feuerstein from Real Money)

I just talked to a source with a copy of the JAMA article mentioned below involving Esperion Therapeutics' (ESPR-Nasdaq) arterial plaque-reducing drug ETC216. And yes, the data is negative.

Without going into a lot of details, the level of arterial plaque reduction in patients given ETC216 compared to patients taking a placebo was NOT statistically significant...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News